Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Pipeline Review, H2 2016’, provides in depth analysis on Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1)

The report reviews Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Arrien Pharmaceuticals, LLC

Bionomics Limited

Novartis AG

OncoTherapy Science, Inc.

Selvita S.A.

SignalChem Lifesciences Corp

Arrien Pharmaceuticals, LLC

Bionomics Limited

Novartis AG

OncoTherapy Science, Inc.

Selvita S.A.

SignalChem Lifesciences Corp

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Maternal Embryonic ...

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) Overview 6

Therapeutics Development 7

Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Products under Development by Stage of Development 7

Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Products under Development by Therapy Area 8

Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Products under Development by Indication 9

Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Products under Development by Companies 12

Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Products under Development by Universities/Institutes 14

Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Companies Involved in Therapeutics Development 22

Arrien Pharmaceuticals, LLC 22

Bionomics Limited 23

Novartis AG 24

OncoTherapy Science, Inc. 25

Selvita S.A. 26

SignalChem Lifesciences Corp 27

Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Drug Profiles 28

ARN-7016 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Drugs to Inhibit MELK for Solid Tumors - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

OTS-167 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

SEL-128 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Small Molecules to Inhibit MELK for Oncology - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Small Molecules to Inhibit MELK for Oncology - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Vaccine to Target FOXM1, MELK, HJURP, VEGFR-1 and VEGFR-2 for Ovarian Cancer - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Dormant Projects 36

Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Featured News & Press Releases 37

Mar 17, 2016: The Phase I clinical study of OTS167, MELK specific inhibitor, in Australia Completed 37

Feb 29, 2016: Publication of a paper describing the possible effect of a MELK inhibitor OTS167 on kidney cancer 37

Feb 26, 2016: Publication for possible biomarkers of OTS167, MELK inhibitor 38

Feb 12, 2016: Publication of a paper describing the possible effect of a MELK inhibitor, OTS167, on small cell lung cancer 38

Jan 25, 2016: The commencement of Phase I/II clinical study of OTS167, MELK specific inhibitor, for Acute Myeloid Leukemia patients in USA 38

Jan 05, 2016: MELK inhibitor, OTS167, Phase I clinical study commencement in Australia 39

Jun 18, 2015: The commencement of patient enrollment in Phase I clinical study of OTS167, a novel small molecule compound targeting cancer stem cells 39

Apr 15, 2013: Selvita Reports Data from SEL128 Oncology Program At AACR Annual Meeting 2013 40

Appendix 41

Methodology 41

Coverage 41

Secondary Research 41

Primary Research 41

Expert Panel Validation 41

Contact Us 41

Disclaimer 42

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of ...

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 17

Number of Products by Stage and Route of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 21

Pipeline by Arrien Pharmaceuticals, LLC, H2 2016 22

Pipeline by Bionomics Limited, H2 2016 23

Pipeline by Novartis AG, H2 2016 24

Pipeline by OncoTherapy Science, Inc., H2 2016 25

Pipeline by Selvita S.A., H2 2016 26

Pipeline by SignalChem Lifesciences Corp, H2 2016 27

Dormant Projects, H2 2016 36

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative ...

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Routes of Administration, H2 2016 18

Number of Products by Stage and Routes of Administration, H2 2016 18

Number of Products by Molecule Types, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 20

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports